Antitumor Effect of Regorafenib on MicroRNA Expression in Hepatocellular Carcinoma Cell Lines.
Carcinoma, Hepatocellular
/ drug therapy
G1 Phase Cell Cycle Checkpoints
/ drug effects
Gene Expression Regulation, Neoplastic
/ drug effects
Hep G2 Cells
Humans
Liver Neoplasms
/ drug therapy
MicroRNAs
/ biosynthesis
Phenylurea Compounds
/ pharmacology
Pyridines
/ pharmacology
RNA, Neoplasm
/ biosynthesis
Resting Phase, Cell Cycle
/ drug effects
antitumor effect
cell cycle
cell proliferation
cyclin
hepatocellular carcinoma
microRNA
regorafenib
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
31 Jan 2022
31 Jan 2022
Historique:
received:
23
12
2021
revised:
25
01
2022
accepted:
27
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
12
3
2022
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and is one of the leading causes of cancer-related deaths worldwide. Regorafenib, a multi-kinase inhibitor, is used as a second-line treatment for advanced HCC. Here, we aimed to investigate the mechanism of the antitumor effect of regorafenib on HCC and evaluate altered microRNA (miRNA) expression. Cell proliferation was examined in six HCC cell lines (HuH-7, HepG2, HLF, PLC/PRF/5, Hep3B, and Li-7) using the Cell Counting Kit-8 assay. Xenografted mouse models were used to assess the effects of regorafenib in vivo. Cell cycle analysis, western blotting analysis, and miRNA expression analysis were performed to identify the antitumor inhibitory potential of regorafenib on HCC cells. Regorafenib suppressed proliferation in HuH-7 cell and induced G0/G1 cell cycle arrest and cyclin D1 downregulation in regorafenib-sensitive cells. During miRNA analysis, miRNA molecules associated with the antitumor effect of regorafenib were found. Regorafenib suppresses cell proliferation and tumor growth in HCC by decreasing cyclin D1 via alterations in intracellular and exosomal miRNAs in HCC.
Identifiants
pubmed: 35163589
pii: ijms23031667
doi: 10.3390/ijms23031667
pmc: PMC8835935
pii:
doi:
Substances chimiques
MicroRNAs
0
Phenylurea Compounds
0
Pyridines
0
RNA, Neoplasm
0
regorafenib
24T2A1DOYB
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Hepatol Res. 2015 Jan;45(2):128-41
pubmed: 25040738
Nat Rev Clin Oncol. 2018 Oct;15(10):599-616
pubmed: 30061739
Sci Rep. 2018 Jul 11;8(1):10461
pubmed: 29992971
Oncotarget. 2017 Jan 31;8(5):7231-7247
pubmed: 27980227
Onco Targets Ther. 2018 Jan 26;11:571-585
pubmed: 29416358
J Exp Clin Cancer Res. 2018 Jan 29;37(1):14
pubmed: 29378599
J Mol Med (Berl). 2016 Dec;94(12):1313-1326
pubmed: 27695879
J Nutr Biochem. 2019 Jan;63:87-100
pubmed: 30359864
Oncol Lett. 2020 Aug;20(2):1727-1733
pubmed: 32724415
Drugs Today (Barc). 2018 Jan;54(1):5-13
pubmed: 29569657
Lancet. 2012 Mar 31;379(9822):1245-55
pubmed: 22353262
Eur J Cancer. 2003 Sep;39(13):1920-6
pubmed: 12932672
Oncotarget. 2017 Jun 27;8(44):76057-76068
pubmed: 29100291
Cancer Res. 2008 Aug 15;68(16):6698-707
pubmed: 18701494
Expert Rev Anticancer Ther. 2017 Jul;17(7):567-576
pubmed: 28580808
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
Liver Int. 2020 Jan;40(1):240-251
pubmed: 31612616
J Clin Med. 2019 Jun 24;8(6):
pubmed: 31238539
Lancet. 2013 Jan 26;381(9863):303-12
pubmed: 23177514
Gastroenterology. 2019 May;156(6):1731-1741
pubmed: 30738047
Cancer Med. 2018 Jun;7(6):2641-2653
pubmed: 29733511
Am J Gastroenterol. 2014 Apr;109(4):542-53
pubmed: 24513805
Int J Cancer. 2011 Jul 1;129(1):245-55
pubmed: 21170960
Int J Oncol. 2005 Mar;26(3):661-71
pubmed: 15703821
Environ Toxicol. 2019 Jun;34(6):679-688
pubmed: 30801954
Stem Cells. 2015 Sep;33(9):2652-63
pubmed: 26013162
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
Clin Cancer Res. 2021 Feb 15;27(4):1150-1161
pubmed: 33288659
PLoS One. 2018 Dec 27;13(12):e0209750
pubmed: 30589909
J Hepatocell Carcinoma. 2017 Jul 11;4:93-103
pubmed: 28744453
Lancet. 2013 Jan 26;381(9863):295-302
pubmed: 23177515
Mol Cancer Ther. 2013 Jul;12(7):1322-31
pubmed: 23619301
Cancer Genomics Proteomics. 2020 Jan-Feb;17(1):1-21
pubmed: 31882547
J Hepatol. 2010 Jan;52(1):88-95
pubmed: 19913321
J Exp Clin Cancer Res. 2019 Nov 26;38(1):474
pubmed: 31771617
Mol Cancer Ther. 2017 Jan;16(1):68-75
pubmed: 27837028
Biomed Pharmacother. 2018 Dec;108:1070-1080
pubmed: 30372807
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4
pubmed: 388439
Cancer Lett. 2019 Jul 1;453:74-83
pubmed: 30928380
Biochem Biophys Res Commun. 2018 Sep 5;503(2):1123-1129
pubmed: 29944884
Anticancer Res. 2019 Nov;39(11):5973-5982
pubmed: 31704822
Oncotarget. 2017 Oct 24;8(61):104090-104103
pubmed: 29262623
Cell Death Dis. 2018 Jan 26;9(2):130
pubmed: 29374140